Company Filing History:
Years Active: 1996
Title: The Innovations of Raymond G. Dunham
Introduction
Raymond G. Dunham is a notable inventor based in San Antonio, TX (US). He has made significant contributions to the field of biomedical research, particularly in the area of atherosclerosis treatment. His innovative work has led to the development of a unique polypeptide that plays a crucial role in inhibiting cholesteryl ester transfer protein (CETP).
Latest Patents
Dunham holds a patent for a CETP inhibitor polypeptide and antibodies against the synthetic polypeptide. This polypeptide and its analogues are designed to inhibit CETP, which is essential in the management of atherosclerosis. The patent outlines an anti-atherosclerosis composition that includes a therapeutically effective amount of the polypeptide along with a pharmaceutically acceptable carrier. Additionally, the patent describes an anti-atherosclerosis kit that contains the composition, a syringe, and a needle. The invention also includes methods for preventing and treating atherosclerosis in mammals by administering the polypeptide.
Career Highlights
Dunham is affiliated with the Southwest Foundation for Biomedical Research, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cardiovascular health and disease prevention.
Collaborations
Some of his notable coworkers include Rampratap Kushwaha and Kathleen Born, who have contributed to the research and development of his innovative projects.
Conclusion
Raymond G. Dunham's contributions to biomedical research, particularly through his patent on CETP inhibitor polypeptides, highlight his role as a significant inventor in the field. His work not only advances scientific understanding but also offers potential solutions for combating atherosclerosis.